Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
Study identifier:D9612C00025
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase III, Multicenter, Open-Label Study To Evaluate the Control of Gastric Acid Secretion with Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome For 12 Months
Medical condition
Zollinger-Ellison Syndrome
Phase
Phase 3
Healthy volunteers
No
Study drug
Esomeprazole magnesium (Nexium)
Sex
All
Actual Enrollment
25
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Nov 2003
Primary Completion Date: -
Study Completion Date: 01 Jul 2005
Study design
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Contact Backup
001-800-236-9933 (Outside US)
-
-
Investigators
Principal Investigator
Nexium Medical Science Director
AstraZeneca
